© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
May 31, 2022
The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
May 28, 2022
Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”
May 25, 2022
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.
May 24, 2022
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
May 13, 2022
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
May 13, 2022
The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.
May 12, 2022
At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.
May 12, 2022
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
May 11, 2022
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
May 11, 2022
Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."